Recently, Camrelizumab, one PD-1 inhibitor, showed antitumor activity in pretreated Chinese patients with advanced hepatocellular carcinoma in a multicenter, open-label, parallel-group, randomized, phase-2 trial (Qin et al., 2020). Here, PDCD1 is linked to hepatocellular carcinoma.